Pulmonary Fibrosis

Pulmonary fibrosis is a disease in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The formation of scar tissue is called fibrosis.

Programs + Services


Pulmonary Hypertension Center

Tufts MC's pulmonary hypertension specialists are experts in providing personalized evaluations and treatment of this potentially serious disease.
More information about programs and services

Doctors + Care Team

Nicholas S. Hill, MD

Nicholas S. Hill, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Chief, Pulmonary, Critical Care and Sleep Division; Professor, Tufts University School of Medicine
Department(s): Medicine, Pulmonary, Critical Care and Sleep Medicine
Appt. Phone: 617-636-6377
Fax #: 617-636-1649

Pulmonary hypertension, mechanical ventilation, noninvasive ventilation, general pulmonology

View Full Profile for Nicholas S. Hill, MD

Ioana R. Preston, MD

Ioana R. Preston, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Pulmonary Function Lab Director; Director, Pulmonary Hypertension Center; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Pulmonary, Critical Care and Sleep Medicine
Appt. Phone: 617-636-6377
Fax #: 617-636-1649

Pulmonary hypertension, critical care medicine, general pulmonology

View Full Profile for Ioana R. Preston, MD

Kari E. Roberts, MD

Kari E. Roberts, MD

Accepting New Patients

Title(s): Associate Chief Medical Officer, Graduate Medical Education; Associate Program Director, Internal Medicine Residency; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Pulmonary, Critical Care and Sleep Medicine
Appt. Phone: 617-636-6377
Fax #: 617-636-1649

General pulmonology, pulmonary hypertension, critical care medicine

View Full Profile for Kari E. Roberts, MD

Sucharita R. Kher, MD

Sucharita R. Kher, MD

Accepting New Patients

Virtual Appointments Available

Title(s): Vice Chair for Clinical Operations and Quality, Department of Medicine; Director, Pulmonary Clinic; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Pulmonary, Critical Care and Sleep Medicine
Appt. Phone: 617-636-6377
Fax #: 617-636-1649

Pulmonary diseases, critical care medicine
Asthma, COPD, Tobacco dependence treatment

View Full Profile for Sucharita R. Kher, MD

Research + Clinical Trials


A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

The primary objective of the study is to evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF. This study hypothesizes that inhaled treprostinil will have a positive effect on absolute FVC after 52 weeks of therapy as compared with placebo when administered to subjects with IPF. This is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.Approximately 396 eligible subjects study-wide will be randomly assigned 1:1 to inhaled treprostinil or placebo at Baseline. Randomization will be stratified by IPF background therapy (nintedanib or pirfenidone vs no background therapy). All subjects will initiate inhaled treprostinil (6 mcg/breath) or placebo at a dose of 3 breaths (18 mcg) administered QID (during waking hours) and will titrate to a target dosing regimen of 12 breaths (72 mcg) QID.
More information about research and clinical trials